Trials / Completed
CompletedNCT00302991
Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)
Quality of Life and Adverse Effects in Epilepsy Patients According to Treatment Group (EPIKA)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 180 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.
Conditions
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-03-15
- Last updated
- 2008-01-30
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00302991. Inclusion in this directory is not an endorsement.